Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Status:
Recruiting
Trial end date:
2025-01-14
Target enrollment:
Participant gender:
Summary
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to
demonstrate the superiority of LNP023 at a dose of 200 mg b.i.d. compared to placebo on top
of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease
progression in primary IgA Nephropathy patients.